Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Epigenome mapping uncovers unique patterns that emerge during generation of brain circuitry

High-resolution mapping of the epigenome has discovered unique patterns that emerge during the generation of brain circuitry in childhood.

6 Jul 2013

Findings uncover epigenomic modification that occurs during brain formation

Changes in the epigenome, including chemical modifications of DNA, can act as an extra layer of information in the genome, and are thought to play a role in learning and memory, as well as in age-related cognitive decline.

5 Jul 2013

ERYTECH reports fast take-off of GRASPA Phase IIb trial in patients with acute myeloid leukemia

ERYTECH, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces a fast take-off of its Phase IIb study in Acute Myeloid Leukemia.

4 Jul 2013

Study shows miR-22 plays a key role in breast and blood cancers

A mere 25 years ago, noncoding RNAs were considered nothing more than "background noise" in the overall genomic landscape. Now, two new studies reveal that one of these tiny noncoding molecules - microRNA-22 - plays an outsized role in two types of cancer.

4 Jul 2013

Genentech's obinutuzumab gets FDA Priority Review for chronic lymphocytic leukemia

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted the company's Biologics License Application for obinutuzumab (GA101) and granted Priority Review for GA101 in the treatment of chronic lymphocytic leukemia, one of the most common forms of blood cancer, based on final Stage 1 data from the pivotal CLL11 trial.

3 Jul 2013

CTI announces publication of preclinical, clinical data for pacritinib in Drugs of the Future 2013

Cell Therapeutics, Inc. today announced that a comprehensive article summarizing preclinical and clinical data for pacritinib, an oral JAK2/FLT3 inhibitor, authored by Srdan Verstovsek, M.D., Ph.D., et al., was published in the journal Drugs of the Future 2013.

3 Jul 2013

Weekend reading: Chemo revolution, Lyme disease confusion and the residency mismatch

Because I've lived so long with anxiety, there were lots of things I figured I'd never, ever do - having children was one of them. In fact, in my 20s, before I'd managed to stumble on the combination of drugs and exercise that allows me to be as sane as I can expect to be, I was so sure I'd never give birth that I got a tattoo of a giant koi fish extending from one end of my abdomen to the other. ... I found myself in a very ironic situation: my decision to have a child was the result of a sense of stability I enjoyed due to taking an array of anti-anxiety medications that I would be strongly advised by most doctors to stop taking now that I was pregnant (Alissa Nutting, 6/23).

28 Jun 2013

UNIGE researchers identify genomic variations associated with trisomy 21

Down syndrome, more commonly known as "trisomy 21" is very often accompanied by pathologies found in the general population: Alzheimer's disease, leukemia, or cardiac deficiency.

28 Jun 2013

Ambit Biosciences presents data from Phase 2 ACE study of quizartinib for treatment of AML

Ambit Biosciences Corporation announced today data from the Phase 2 ACE study of quizartinib (AC220), a FLT3 inhibitor, were featured in multiple presentations at the 18th Congress of the European Hematology Association in Stockholm, Sweden.

27 Jun 2013

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013

New study provides guidelines for stem cell transplantation in older MDS patients

A new study by an international team led by Dana-Farber Cancer Institute scientists provides the first statistically-based guidelines for determining whether a stem cell transplant is appropriate for older patients with myelodysplastic syndromes - the most common blood disorders in people over 60 years of age, and frequently a precursor for leukemia.

25 Jun 2013

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with advanced hematologic malignancies, or potentially fatal blood cancers.

25 Jun 2013

CytRx reaches targeted enrollment in aldoxorubicin Phase 2b study for treatment of soft tissue sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced that it has reached the targeted enrollment of 105 evaluable patients in its international Phase 2b clinical trial with aldoxorubicin as a first-line treatment for soft tissue sarcoma.

25 Jun 2013

Investigators uncover connection between tumor metabolic process and progression of kidney cancer

Investigators in The Cancer Genome Atlas (TCGA) Research Network have uncovered a connection between how tumor cells use energy from metabolic processes and the aggressiveness of the most common form of kidney cancer, clear cell renal cell carcinoma (ccRCC).

24 Jun 2013

Research findings suggest potent new therapeutic target for certain types of cancer

Scientists have discovered the survival secret to a genetic mutation that stokes leukemia cells, solving an evolutionary riddle and paving the way to a highly targeted therapy for leukemia.

21 Jun 2013

TSRI scientists receive NIH grant to create new drug for chronic lymphocytic leukemia

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded more than $1.4 million from the National Cancer Institute of the National Institutes of Health to create a potential new drug to attack the malignant cells that cause chronic lymphocytic leukemia (CLL), which is the most common leukemia in the Western world.

20 Jun 2013

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL).

20 Jun 2013

Results of ibrutinib Phase 2 study in patients with mantle cell lymphoma published in NEJM

Pharmacyclics, Inc. today announced that The New England Journal of Medicine published results of a Phase 2 study evaluating the investigational oral Bruton's tyrosine kinase inhibitor ibrutinib in patients with relapsed/refractory mantle cell lymphoma online.

20 Jun 2013

MCL-1 protein is vital for normal heart function, shows study

A study by researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences and the Department of Pharmacology at the University of California, San Diego, shows that a protein called MCL-1, which promotes cell survival, is essential for normal heart function.

18 Jun 2013

Targeting SALL4 protein with druglike molecules could halt tumor growth, say researchers

Harvard Stem Cell Institute researchers have identified in the most aggressive forms of cancer a gene known to regulate embryonic stem cell self-renewal, beginning a creative search for a drug that can block its activity.

18 Jun 2013

Leukemia News and Research

Further Reading

Epigenome mapping uncovers unique patterns that emerge during generation of brain circuitry

Findings uncover epigenomic modification that occurs during brain formation

ERYTECH reports fast take-off of GRASPA Phase IIb trial in patients with acute myeloid leukemia

Study shows miR-22 plays a key role in breast and blood cancers

Genentech's obinutuzumab gets FDA Priority Review for chronic lymphocytic leukemia

CTI announces publication of preclinical, clinical data for pacritinib in Drugs of the Future 2013

Weekend reading: Chemo revolution, Lyme disease confusion and the residency mismatch

UNIGE researchers identify genomic variations associated with trisomy 21

Ambit Biosciences presents data from Phase 2 ACE study of quizartinib for treatment of AML

Eisai submits BELVIQ NDS with Health Canada

New study provides guidelines for stem cell transplantation in older MDS patients

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

CytRx reaches targeted enrollment in aldoxorubicin Phase 2b study for treatment of soft tissue sarcoma

Investigators uncover connection between tumor metabolic process and progression of kidney cancer

Research findings suggest potent new therapeutic target for certain types of cancer

TSRI scientists receive NIH grant to create new drug for chronic lymphocytic leukemia

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

Results of ibrutinib Phase 2 study in patients with mantle cell lymphoma published in NEJM

MCL-1 protein is vital for normal heart function, shows study

Targeting SALL4 protein with druglike molecules could halt tumor growth, say researchers

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News